BioIntelliSense

Overview
Activities
News
Preventive Healthcare?
Product stageSegments
Expansion
?
Passive Remote Monitoring Platforms
?

BioIntelliSense is a passive remote patient monitoring company offering a medical-grade Data-as-a-Service (DaaS) platform that captures multi-parameter vital signs and physiological biometrics for chronic care management and early disease detection. Its key offering is the BioButton, a disposable wearable device that continuously captures the vital signs of patients for 30 days. The company claims it is an industry-first multi-parameter wearable device for remote patient monitoring that is capable of transmitting up to 1,440 vital signs per day.

The company’s continuous monitoring solutions are used both in-hospital and for remote monitoring in therapeutic areas such as oncology, orthopedic, maternal health, and complex care. In October 2024, received FDA clearance for its rechargeable BioButton Multi-Patient wearable and BioDashboard system. It operates a B2B2C business model, partnering with several healthcare providers. 

In October 2022, the company acquired patient monitoring platform AlertWatch for an undisclosed sum to expand it’s remote patient monitoring offerings by incorporating AlertWatch into its BioButton remote patient wearable. 

Key customers and partnerships

The company has several collaborations to scale the development of its devices including UCHealth and CARE Innovation Center. In November 2022, the company partnered with the Translational Research Institute to study human health in space using the BioButton. 

The company has also established several key customers to expand its products; these include partnerships with 1) Mubadala Health to expand its offerings to healthcare providers in the UAE (March 2022), 2) UC Davis Health and Houston Methodist to deploy its platform at the center (May 2022/November 2023), 3)Medtronic plc to provide Medtronic an exclusive license to distribute Biobutton to US hospitals via its remote patient monitoring solutions (August 2022), 4) Ardent Health Services to use the BioButton across Ardent’s 30 hospitals for remote monitoring (November 2022), and 5) care.ai to integrate their technologies in optimizing clinical operations at healthcare facilities (January 2023).

HQ location:
Golden, CO, 80401 Golden CO USA
Founded year:
2018
Employees:
101-250
IPO status:
Private
Total funding:
USD 84.8 mn
Last Funding:
USD 45.0 mn (Series B; Jul 2021)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.